1 |
Tang L, Wang T, Zhang Q, Yu S, Li W, Yao S, Cheng H. Safety and Efficacy of Treatment with/without Ramucirumab in Advanced or Metastatic Cancer: A Meta-Analysis of 11 Global, Double-Blind, Phase 3 Randomized Controlled Trials. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/2476469] [Reference Citation Analysis]
|
2 |
Xiudan Han, Wei Long, Ying Liu, Jixiong Xu. Prognostic value and immunological role of BAIAP2L2 in liver hepatocellular carcinoma: A pan-cancer analysis. Front Surg 2022;9:985034. [PMID: 36338652 DOI: 10.3389/fsurg.2022.985034] [Reference Citation Analysis]
|
3 |
Xue C, Gu X, Zhao Y, Jia J, Zheng Q, Su Y, Bao Z, Lu J, Li L. Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes. Cancer Cell Int 2022;22:308. [PMID: 36217206 DOI: 10.1186/s12935-022-02730-8] [Reference Citation Analysis]
|
4 |
Jia W, Yu L, Xu B, Feng Y, Wang J, Chu J, Zhu D, Xu C, Zhou Y, Kong L, Ding W. BAIAP2L2 is activated by NFκB1 and promotes the malignancy of hepatocellular carcinoma by suppressing the ubiquitin-mediated degradation of GABPB1 to activate TRET transcription.. [DOI: 10.21203/rs.3.rs-1945634/v1] [Reference Citation Analysis]
|
5 |
Iacobas S, Iacobas DA. A Personalized Genomics Approach of the Prostate Cancer. Cells 2021;10:1644. [PMID: 34209090 DOI: 10.3390/cells10071644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|